RE: Re: Brazil8 Nov 2020 07:22
Mon, 2nd Nov 2020 07:00
RNS Number : 8499D
Tiziana Life Sciences PLC
02 November 2020
Tiziana Life Sciences PLC
("Tiziana" or "the Company")
Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
London/New York, 2 November 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces initiation of a collaborative clinical study investigating nasally administered Foralumab either alone or in combination with orally administered dexamethasone in COVID-19 patients in Brazil. In view of the importance and urgency, scientific teams at the Harvard Medical School, Santa Casa de Misericórdia de Santos Hospital (Jabaquara, Santos, Brazil) and at Tiziana are closely collaborating to facilitate initiation of this study in expedited time frames. This clinical trial will be coordinated by the team at INTRIALS, a leading, full-service Latin America Clinical Research Organisation, (CRO) based in Sao Paulo City, Brazil. The clinical data from this trial is expected to be available by the end of this year.